Description of Medical ServiceThe proposed service is a novel form of brachytherapy for non-melanoma skin cancer (NMSC), which uses the Beta emitter radioisotope Rhenium-188. During treatment, the affected area of the skin is covered with the sterile protective foil. The Rhenium-188 is then applied in a matrix on the foil using a special applicator device. The irradiation time required to achieve the desired target dose at the defined penetration depth is calculated based on the radioactivity of the substance being applied and the surface area to be treated. After the calculated irradiation time, the matrix is removed by pulling the foil from the skin. It can be provided without anaesthesia, over a short period of time in an outpatient setting.
Description of Medical ConditionNMSC, also known as keratinocyte cancer, includes basal cell carcinoma, squamous cell carcinoma, and various other less common lesions. The most common cause of NMSC is sun exposure, while other predisposing factors include genetic skin conditions and immunosuppressive diseases or treatments.
Reason for ApplicationNew MBS item
Medical Service TypeTherapeutic
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1070 KB)
Application Form (Word 162 KB)
Consultation SurveyConsultation Survey (PDF 690 KB)
Consultation Survey (Word 72 KB)
MSAC consultation input must be received by no later than Friday, 9 June 2023 for it to be considered by MSAC at its July 2023 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process
PICO ConfirmationPICO Confirmation (PDF 728 KB)
PICO Confirmation (Word 530 KB)